Letter | Published:

A high-frequency phenotypic switch links bacterial virulence and environmental survival in Acinetobacter baumannii

Nature Microbiologyvolume 3pages563569 (2018) | Download Citation

Abstract

Antibiotic-resistant infections lead to 700,000 deaths per year worldwide1. The roles of phenotypically diverse subpopulations of clonal bacteria in the progression of diseases are unclear. We found that the increasingly pathogenic and antibiotic-resistant pathogen Acinetobacter baumannii harbours a highly virulent subpopulation of cells responsible for disease. This virulent subpopulation possesses a thicker capsule and is resistant to host antimicrobials, which drive its enrichment during infection. Importantly, bacteria harvested from the bloodstream of human patients belong exclusively to this virulent subpopulation. Furthermore, the virulent form exhibits increased resistance to hospital disinfectants and desiccation, indicating a role in environmental persistence and the epidemic spread of disease. We identified a transcriptional ‘master regulator’ of the switch between avirulent and virulent cells, the overexpression of which abrogates virulence. Furthermore, the overexpression strain is capable of vaccinating mice against lethal challenge. This work highlights a phenotypic subpopulation of bacteria that drastically alters the outcome of infection, and illustrates how knowledge of the regulatory mechanisms controlling such phenotypic switches can be harnessed to attenuate bacteria and develop translational interventions.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    O’Neill, J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations (UK Government & Wellcome Trust, 2014); https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf

  2. 2.

    Bergogne-Berezin, E. & Towner, K. J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9, 148–165 (1996).

  3. 3.

    Antunes, L. C., Visca, P. & Towner, K. J. Acinetobacter baumannii: evolution of a global pathogen. Pathog. Dis. 71, 292–301 (2014).

  4. 4.

    Dijkshoorn, L., Nemec, A. & Seifert, H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5, 939–951 (2007).

  5. 5.

    Joly-Guillou, M. L. Clinical impact and pathogenicity of Acinetobacter. Clin. Microbiol. Infect. 11, 868–873 (2005).

  6. 6.

    Murray, C. K. & Hospenthal, D. R. Acinetobacter infection in the ICU. Crit. Care Clin. 24, 237–248 (2008).

  7. 7.

    Charnot-Katsikas, A. et al. Two cases of necrotizing fasciitis due to Acinetobacter baumannii. J. Clin. Microbiol. 47, 258–263 (2009).

  8. 8.

    Guerrero, D. M. et al. Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease. Surg. Infect. 11, 49–57 (2010).

  9. 9.

    Lowman, W., Kalk, T., Menezes, C. N., John, M. A. & Grobusch, M. P. A case of community-acquired Acinetobacter baumannii meningitis—has the threat moved beyond the hospital? J. Med. Microbiol. 57, 676–678 (2008).

  10. 10.

    Telang, N. V., Satpute, M. G., Dhakephalkar, P. K., Niphadkar, K. B. & Joshi, S. G. Fulminating septicemia due to persistent pan-resistant community-acquired metallo-beta-lactamase (IMP-1)-positive Acinetobacter baumannii. Indian J. Pathol. Microbiol. 54, 180–182 (2011).

  11. 11.

    Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1–12 (2009).

  12. 12.

    Doi, Y., Husain, S., Potoski, B. A., McCurry, K. R. & Paterson, D. L. Extensively drug-resistant Acinetobacter baumannii. Emerg. Infect. Dis. 15, 980–982 (2009).

  13. 13.

    Gottig, S. et al. Detection of pan drug-resistant Acinetobacter baumannii in Germany. J. Antimicrob. Chemother. 69, 2578–2579 (2014).

  14. 14.

    Lei, J. et al. Extensively drug-resistant Acinetobacter baumannii outbreak cross-transmitted in an intensive care unit and respiratory intensive care unit. Am. J. Infect. Control 44, 1280–1284 (2016).

  15. 15.

    Park, Y. K. et al. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg. Infect. Dis. 15, 1325–1327 (2009).

  16. 16.

    Maragakis, L. L. & Perl, T. M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46, 1254–1263 (2008).

  17. 17.

    Villegas, M. V. & Hartstein, A. I. Acinetobacter outbreaks, 1977–2000. Infect. Control Hosp. Epidemiol. 24, 284–295 (2003).

  18. 18.

    Fernandez-Cuenca, F. et al. Reduced susceptibility to biocides in Acinetobacter baumannii: association with resistance to antimicrobials, epidemiological behaviour, biological cost and effect on the expression of genes encoding porins and efflux pumps. J. Antimicrob. Chemother. 70, 3222–3229 (2015).

  19. 19.

    Jawad, A., Seifert, H., Snelling, A. M., Heritage, J. & Hawkey, P. M. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J. Clin. Microbiol. 36, 1938–1941 (1998).

  20. 20.

    Hassan, K. A. et al. Transcriptomic and biochemical analyses identify a family of chlorhexidine efflux proteins. Proc. Natl Acad. Sci. USA 110, 20254–20259 (2013).

  21. 21.

    Brooks, S. E., Walczak, M. A., Hameed, R. & Coonan, P. Chlorhexidine resistance in antibiotic-resistant bacteria isolated from the surfaces of dispensers of soap containing chlorhexidine. Infect. Control Hosp. Epidemiol. 23, 692–695 (2002).

  22. 22.

    Jacobs, A. C. et al. AB5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. mBio 5, e01076–14 (2014).

  23. 23.

    Tipton, K. A., Dimitrova, D. & Rather, P. N. Phase-variable control of multiple phenotypes in Acinetobacter baumannii strain AB5075. J. Bacteriol. 197, 2593–2599 (2015).

  24. 24.

    Geisinger, E. & Isberg, R. R. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 11, e1004691 (2015).

  25. 25.

    Martin, T. R. & Frevert, C. W. Innate immunity in the lungs. Proc. Am. Thorac. Soc. 2, 403–411 (2005).

  26. 26.

    Hiemstra, P. S., McCray, P. B. Jr & Bals, R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur. Respir. J. 45, 1150–1162 (2015).

  27. 27.

    Tipton, K. A. & Rather, P. N. An ompR–envZ two-component system ortholog regulates phase variation, osmotic tolerance, motility, and virulence in Acinetobacter baumannii strain AB5075. J. Bacteriol. 199, e00705-16 (2016).

  28. 28.

    Tipton, K. A., Farokhyfar, M. & Rather, P. N. Multiple roles for a novel RND-type efflux system in Acinetobacter baumannii AB5075. MicrobiologyOpen 6, e00418 (2016).

  29. 29.

    Regeimbal, J. M. et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob. Agents Chemother. 60, 5806–5816 (2016).

  30. 30.

    Slutsky, B. et al. “White–opaque transition”: a second high-frequency switching system in Candida albicans. J. Bacteriol. 169, 189–197 (1987).

  31. 31.

    Turner, K. H., Vallet-Gely, I. & Dove, S. L. Epigenetic control of virulence gene expression in Pseudomonas aeruginosa by a LysR-type transcription regulator. PLoS Genet. 5, e1000779 (2009).

  32. 32.

    Diard, M. et al. Stabilization of cooperative virulence by the expression of an avirulent phenotype. Nature 494, 353–356 (2013).

  33. 33.

    Ronin, I., Katsowich, N., Rosenshine, I. & Balaban, N. Q. A long-term epigenetic memory switch controls bacterial virulence bimodality. eLife 6, e19599 (2017).

  34. 34.

    Mouammine, A. et al. An antimicrobial peptide-resistant minor subpopulation of Photorhabdus luminescens is responsible for virulence. Sci. Rep. 7, 43670 (2017).

  35. 35.

    Bommanavar, S. B., Gugwad, S. & Malik, N. Phenotypic switch: the enigmatic white–gray–opaque transition system of Candida albicans. J. Oral. Maxillofac. Pathol. 21, 82–86 (2017).

  36. 36.

    Hunger, M., Schmucker, R., Kishan, V. & Hillen, W. Analysis and nucleotide sequence of an origin of DNA replication in Acinetobacter calcoaceticus and its use for Escherichia coli shuttle plasmids. Gene 87, 45–51 (1990).

  37. 37.

    Hoang, T., Karkhoff-Schweizer, R., Kutchma, A. & Schweizer, H. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212, 77–86 (1998).

  38. 38.

    Choi, K. & Schweizer, H. mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa. Nat. Protoc. 1, 153–161 (2006).

Download references

Acknowledgements

The authors thank staff at the Genomics Resource Center at the University of Maryland for help with RNA-Seq and analysis, H. Ratner for the mice experiments, D. Bonenberger for breeding the knockout mice and W. Shafer for comments on the manuscript. This study was supported in part by the Robert P. Apkarian Integrated Electron Microscopy Core, which is subsidized by the Emory College of Arts and Sciences and the Emory University School of Medicine, and is one of the Emory Integrated Core Facilities. Additional support was provided by the Georgia Clinical and Translational Science Alliance of the National Institutes of Health (NIH) under award number UL1TR000454. P.N.R is supported by NIH grants R21AI115183 and R01072219, VA Merit award I01 BX001725 and a Research Career Scientist Award from the Department of Veterans Affairs. D.S.W. is supported by a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award, VA Merit award I01 BX002788 and NIH grant AI098800. This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and Department of Veterans Affairs.

Author information

Author notes

  1. These authors contributed equally: Chui Yoke Chin and Kyle A. Tipton.

Affiliations

  1. Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA

    • Chui Yoke Chin
    •  & David S. Weiss
  2. Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA, USA

    • Chui Yoke Chin
    •  & David S. Weiss
  3. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

    • Chui Yoke Chin
    • , Eileen M. Burd
    •  & David S. Weiss
  4. Emory Antibiotic Resistance Center, Emory University School of Medicine, Atlanta, GA, USA

    • Chui Yoke Chin
    • , Eileen M. Burd
    • , David S. Weiss
    •  & Philip N. Rather
  5. Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA

    • Kyle A. Tipton
    •  & Philip N. Rather
  6. Research Service, Atlanta VA Medical Center, Decatur, GA, USA

    • Marjan Farokhyfar
    • , David S. Weiss
    •  & Philip N. Rather
  7. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA

    • Eileen M. Burd

Authors

  1. Search for Chui Yoke Chin in:

  2. Search for Kyle A. Tipton in:

  3. Search for Marjan Farokhyfar in:

  4. Search for Eileen M. Burd in:

  5. Search for David S. Weiss in:

  6. Search for Philip N. Rather in:

Contributions

C.Y.C., K.A.T. and M.F. conducted the experiments. C.Y.C., K.A.T., D.S.W. and P.N.R prepared the manuscript. E.M.B. provided the samples from human patients. D.S.W. and P.N.R. planned and directed the study.

Competing interests

The authors declare no competing interests.

Corresponding authors

Correspondence to David S. Weiss or Philip N. Rather.

Supplementary information

  1. Supplementary Information

    Supplementary Figures 1–13

  2. Reporting Summary

  3. Supplementary Table 1

    Differential expressed genes in AV-T relative to VIR-O. ABUW_1645-regulated genes are highlighted in blue.

About this article

Publication history

Received

Accepted

Published

Issue Date

DOI

https://doi.org/10.1038/s41564-018-0151-5

Further reading